The global systemic
lupus erythematosus market size
is expected to reach USD 3.08 billion by 2025, according to a new report by
Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast
period.Introduction of new biological therapies, which will add to treatment
alternatives and medication costs, in the development pipeline is estimated to
fuel revenue generation of the market. Certain new promising drugs that are
currently in Phase III trials are anticipated to augment the market as these
drugs may target the lupus nephritis patient subset with few effective
alternatives and significant unmet needs to be met. This factor is likely to
have a strong impact on the market as nearly 50.0% of SLE patients suffer with
lupus nephritis.
Use of approved biologic, Benlysta, through
clinical studies, has revealed drastic improvements and substantial decrease in
consumption of anti-inflammatory glucocorticoids in moderate SLE cases. GSK’s
current initiatives center on further increasing opportunities for Benlysta.
The company is conducting indication expansion clinical trials, combination
therapy studies with rituximab, and new product development, to widen
opportunities for its therapy. In this direction, recent launch of Benlysta’s
subcutaneous formulation in several countries is expected to boost the SLE
market over the forecast period.
Browse
Research Report on Systemic Lupus Erythematosus Market:
Further key findings from the study suggest:
·
North America was the major contributor for
the SLE market revenue in 2017 and is anticipated to rise at a CAGR of 8.1%
during the forecast period. This is due to availability of reimbursement and
better healthcare infrastructure and accessibility to biologics.
·
Europe was ranked as the second largest
regional market in the SLE market in 2017 and is expected to register a CAGR of
5.5% over the forecast period
·
Immunosuppressants held the largest share
in the market in 2017 due to their low cost and high accessibility, whereas the
biologics segment is projected to post the highest CAGR during the same period
·
In 2017, the oral segment held the dominant
share of over 54.0% in the market, followed by the intravenous segment that
requires trained medical personnel for administration. Over the forecast years,
the latter is poised to expand at a CAGR of 10.4%
·
Key players in this space include
GlaxoSmithKline, Roche, Pfizer, Novartis, Bayer, and Sanofi. By 2025, other
companies such as ImmuPharma, Aurinia Pharmaceuticals, and Astra Zeneca are
anticipated to enter the SLE market.
View more reports of this
category by Grand View Research at
Grand
View Research has segmented the global systemic lupus erythematosus market by
drug class, route of administration, and region:
Systemic Lupus Erythematosus Drug Classes Outlook (Revenue, USD Million,
2014 - 2025)
·
NSAIDs
·
Corticosteroids
·
Antimalarials
·
Immunosuppressants
·
Biologics
Systemic Lupus Erythematosus Route of Administration Outlook (Revenue,
USD Million, 2014 - 2025)
·
Oral
·
Intravenous
·
Subcutaneous
Systemic Lupus Erythematosus Regional Outlook (Revenue, USD Million,
2014 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Greece
o Sweden
o Norway
o Poland
o RoE
·
Asia Pacific
·
Latin America
o Brazil
o Mexico
o Argentina
·
MEA
View press release of this
research report by Grand View Research:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials, and healthcare.
